Puma Biotech says cancer drug fails mid-stage study

November 13, 2014 10:31 PM

10 0

(Reuters) - Puma Biotechnology Inc said its cancer drug failed as a primary treatment for breast cancer patients in a mid-stage study, sending its shares down 14 percent in extended trading.

The company said the drug, neratinib, did not significantly improve disease-free survival when given in combination with chemotherapy agent paclitaxel as a primary treatment.

Also read: Analysts See $1.05 EPS for McCormick & Company, (MKC); Maltese Capital Management Increased By $9.47 Million Its Comerica (CMA) Holding

Read more

To category page